11:04 AM EDT, 05/15/2024 (MT Newswires) -- CASI Pharmaceuticals ( CASI ) said Wednesday that it has received clearance from the US Food and Drug Administration to proceed with a phase 1/2 trial of CID-103 in adults with chronic Immune Thrombocytopenia, a type of platelet disorder.

The company said that it submitted its Investigational New Drug Application to the regulator on April 12.

Shares of CASI Pharmaceuticals ( CASI ) were nearly 4% higher in recent trading activity.

Price: 3.26, Change: +0.12, Percent Change: +3.95